

Special Issue

Involvement of Body Fluids in SARS-CoV-2 Infection

Message from the Guest Editor

SARS-CoV-2 RNA, or infectious virions, have been detected in various body fluids and secretions such as respiratory aerosols, saliva, bronchoalveolar lavage, plasma, breast milk or feces. Whether or not virus transmissions via all of these body fluids can occur is not entirely understood, but might be dependent on the virus origin and titers in the respective fluid. In this Special Issue of *Viruses*, we want to explore how SARS-CoV-2 enters and behaves in different body fluids or how the different body fluids impact SARS-CoV-2 infectivity. Biological fluids might contain antiviral activities that are based on peptides, proteins, lipids, or extracellular vesicles. The understanding of what environment virus transmissions are likely, or why some transmission routes can be excluded, might reveal points of vulnerability of SARS-CoV-2 and lead to the development of new antiviral strategies. Thus, we here want to accumulate data on virus-interfering or -promoting substances in body fluids and drive the development of antiviral strategies crucially required to fight this and future pandemics.

Guest Editor

Dr. Janis Müller

Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany

Deadline for manuscript submissions

closed (30 April 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/82091

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).